UniQuest is developing a novel, exciting first-in-class oral therapy for the treatment of prostate cancer. The company's candidates have shown significant anti-tumour activity in a prostate cancer model comparable to the current standard of care.
In the US there were an estimated 174,650 newly diagnosed cases of prostate cancer in 2019. There is an urgent need for more effective treatments with improved safety and quality of life for cancer patients. By targeting a novel non-hormonal mechanism in prostate cancer, the company is developing treatments for patients who have become resistant to standard of care and have high expression levels of the target, also providing a safer alternative to chemotherapy.
UniQuest's drug discovery unit, The Queensland Emory Drug Discovery Initiative (QEDDI), is progressing the novel compounds towards preclinical development. With BTB support, the team intends to progress its candidate compounds for the treatment of prostate cancer. Additionally, they are exploring the efficacy of their candidates in the treatment of other cancers, such as breast cancer.
QEDDI's team of industry-experienced drug discovery scientists collaborate with academic researchers to translate and commercialise biomedical research to provide improved treatments for patients with considerable unmet need. UniQuest is the technology transfer company of The University of Queensland (UQ).
Established in 1984, UniQuest's commercialisation activities have placed UQ at the forefront of academic research translation in Australia. Working at the interface between industry and UQ's researchers, UniQuest identifies, protects, manages and commercialises UQ's intellectual property, creating impact from the outcomes of research
BTB Round: Two
Project Partner:The University of Queensland
- MTPConnect Grant: $989,140
- Industry Contribution: $1,545,343
Duration: July 2020 – June 2022
Contact: Terrie-Anne Cock